{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:48:52Z","timestamp":1793216932390,"version":"4.5.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20221042"],"award-info":[{"award-number":["BK20221042"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304428"],"award-info":[{"award-number":["82304428"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Biomed. Eng"],"DOI":"10.1038\/s41551-025-01555-w","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T10:02:17Z","timestamp":1763373737000},"page":"1898-1914","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["HBsAg-tagged tumour vaccine system eliminates solid tumours through virus-specific memory T cells"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7906-3779","authenticated-orcid":false,"given":"Wenguang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihang","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0007-1429","authenticated-orcid":false,"given":"Xianjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3656-7143","authenticated-orcid":false,"given":"Yiqiao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9649-1200","authenticated-orcid":false,"given":"Shuguang","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1038-9470","authenticated-orcid":false,"given":"Yong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"1555_CR1","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nri.2017.131","volume":"18","author":"Z Hu","year":"2018","unstructured":"Hu, Z., Ott, P. A. & Wu, C. J. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat. Rev. Immunol. 18, 168\u2013182 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"1555_CR2","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","volume":"18","author":"E Blass","year":"2021","unstructured":"Blass, E. & Ott, P. A. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat. Rev. Clin. Oncol. 18, 215\u2013229 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1555_CR3","doi-asserted-by":"publisher","first-page":"CT301","DOI":"10.1158\/1538-7445.AM2020-CT301","volume":"80","author":"JS Lopez","year":"2020","unstructured":"Lopez, J. S. et al. A phase Ib study to evaluate RO7198457, an individualized neoantigen specific immunotherapy (iNeST),in combination with atezolizumab in patients with locally advanced or metastatic solid tumors. Cancer Res. 80, CT301 (2020).","journal-title":"Cancer Res."},{"key":"1555_CR4","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.1158\/1078-0432.CCR-19-2881","volume":"26","author":"Y Fang","year":"2020","unstructured":"Fang, Y. et al. A pan-cancer clinical study of personalized neoantigen vaccine monotherapy in treating patients with various types of advanced solid tumors. Clin. Cancer Res. 26, 4511\u20134520 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1555_CR5","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1016\/j.cell.2022.06.035","volume":"185","author":"MC Sellars","year":"2022","unstructured":"Sellars, M. C., Wu, C. J. & Fritsch, E. F. Cancer vaccines: building a bridge over troubled waters. Cell 185, 2770\u20132788 (2022).","journal-title":"Cell"},{"key":"1555_CR6","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41573-021-00387-y","volume":"21","author":"F Lang","year":"2022","unstructured":"Lang, F., Schrors, B., Lower, M., Tureci, O. & Sahin, U. Identification of neoantigens for individualized therapeutic cancer vaccines. Nat. Rev. Drug Discov. 21, 261\u2013282 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1555_CR7","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41586-021-03752-4","volume":"596","author":"JX Caushi","year":"2021","unstructured":"Caushi, J. X., et al. Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature 596, 126\u2013132 (2021).","journal-title":"Nature"},{"key":"1555_CR8","doi-asserted-by":"publisher","first-page":"479\u2013485","DOI":"10.1038\/s41586-019-1032-7","volume":"567","author":"R Rosenthal","year":"2019","unstructured":"Rosenthal, R. et al. Neoantigen-directed immune escape in lung cancer evolution. Nature 567, 479\u2013485 (2019).","journal-title":"Nature"},{"key":"1555_CR9","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/s41573-021-00155-y","volume":"20","author":"SP Kubli","year":"2021","unstructured":"Kubli, S. P., Berger, T., Araujo, D. V., Siu, L. L. & Mak, T. W. Beyond immune checkpoint blockade: emerging immunological strategies. Nat. Rev. Drug Discov. 20, 899\u2013919 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1555_CR10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","volume":"16","author":"JS O\u2019Donnell","year":"2019","unstructured":"O\u2019Donnell, J. S., Teng, M. W. L. & Smyth, M. J. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat. Rev. Clin. Oncol. 16, 151\u2013167 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1555_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","volume":"19","author":"L Kraehenbuehl","year":"2022","unstructured":"Kraehenbuehl, L., Weng, C. H., Eghbali, S., Wolchok, J. D. & Merghoub, T. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat. Rev. Clin. Oncol. 19, 37\u201350 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1555_CR12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41577-023-00937-y","volume":"24","author":"PD Katsikis","year":"2024","unstructured":"Katsikis, P. D., Ishii, K. J. & Schliehe, C. Challenges in developing personalized neoantigen cancer vaccines. Nat. Rev. Immunol. 24, 213\u2013227 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"1555_CR13","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1038\/s41590-023-01578-y","volume":"24","author":"MW Rudloff","year":"2023","unstructured":"Rudloff, M. W. et al. Hallmarks of CD8+ T cell dysfunction are established within hours of tumor antigen encounter before cell division. Nat. Immunol. 24, 1527\u20131539 (2023).","journal-title":"Nat. Immunol."},{"key":"1555_CR14","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.immuni.2021.06.013","volume":"54","author":"Y Cheng","year":"2021","unstructured":"Cheng, Y. et al. Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 54, 1825\u20131840.e7 (2021).","journal-title":"Immunity"},{"key":"1555_CR15","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0168-8278(01)00264-1","volume":"36","author":"Y Sobao","year":"2002","unstructured":"Sobao, Y. et al. The role of hepatitis B virus-specific memory CD8 T cells in the control of viral replication. J. Hepatol. 36, 105\u2013115 (2002).","journal-title":"J. Hepatol."},{"key":"1555_CR16","doi-asserted-by":"publisher","first-page":"44\u201353","DOI":"10.1038\/s41551-021-00834-6","volume":"6","author":"WG Wang","year":"2022","unstructured":"Wang, W. G. et al. Systemic immune responses to irradiated tumours via the transport of antigens to the tumour periphery by injected flagellate bacteria. Nat. Biomed. Eng. 6, 44\u201353 (2022).","journal-title":"Nat. Biomed. Eng."},{"key":"1555_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09389-2","volume":"10","author":"W Wang","year":"2019","unstructured":"Wang, W. et al. Perfluorocarbon regulates the intratumoural environment to enhance hypoxia-based agent efficacy. Nat. Commun. 10, 1580 (2019).","journal-title":"Nat. Commun."},{"key":"1555_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2020.05.013","volume":"487","author":"X Tang","year":"2020","unstructured":"Tang, X. et al. Adenovirus-mediated specific tumor tagging facilitates CAR-T therapy against antigen-mismatched solid tumors. Cancer Lett. 487, 1\u20139 (2020).","journal-title":"Cancer Lett."},{"key":"1555_CR19","doi-asserted-by":"publisher","first-page":"e002843","DOI":"10.1136\/jitc-2021-002843","volume":"9","author":"S Zuo","year":"2021","unstructured":"Zuo, S. et al. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade. J. Immunother. Cancer 9, e002843 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"1555_CR20","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1093\/jnci\/91.20.1744","volume":"91","author":"MFX Gnant","year":"1999","unstructured":"Gnant, M. F. X. et al. Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases. J. Natl Cancer Inst. 91, 1744\u20131750 (1999).","journal-title":"J. Natl Cancer Inst."},{"key":"1555_CR21","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3390\/cancers12040775","volume":"12","author":"S Nakano","year":"2020","unstructured":"Nakano, S. et al. Recent advances in immunotherapy for hepatocellular carcinoma. Cancers 12, 775 (2020).","journal-title":"Cancers"},{"key":"1555_CR22","doi-asserted-by":"publisher","first-page":"e001486","DOI":"10.1136\/jitc-2020-001486","volume":"8","author":"N Macedo","year":"2020","unstructured":"Macedo, N., Miller, D. M., Haq, R. & Kaufman, H. L. Clinical landscape of oncolytic virus research in 2020. J. Immunother. Cancer 8, e001486 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"1555_CR23","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1016\/j.cell.2023.06.002","volume":"186","author":"L Ma","year":"2023","unstructured":"Ma, L. et al. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. Cell 186, 3148\u20133165 (2023).","journal-title":"Cell"},{"key":"1555_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38751-8","volume":"14","author":"W Tai","year":"2023","unstructured":"Tai, W. et al. An mRNA-based T-cell-inducing antigen strengthens COVID-19 vaccine against SARS-CoV-2 variants. Nat. Commun. 14, 2962 (2023).","journal-title":"Nat. Commun."},{"key":"1555_CR25","doi-asserted-by":"publisher","first-page":"3990","DOI":"10.1111\/ajt.16818","volume":"21","author":"T Schmidt","year":"2021","unstructured":"Schmidt, T. et al. Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients. Am. J. Transpl. 21, 3990\u20134002 (2021).","journal-title":"Am. J. Transpl."},{"key":"1555_CR26","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217\u2013221 (2017).","journal-title":"Nature"},{"key":"1555_CR27","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s13238-020-00707-9","volume":"11","author":"Q Liu","year":"2020","unstructured":"Liu, Q., Sun, Z. & Chen, L. Memory T cells: strategies for optimizing tumor immunotherapy. Protein Cell 11, 549\u2013564 (2020).","journal-title":"Protein Cell"},{"key":"1555_CR28","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41392-023-01718-8","volume":"8","author":"M Guo","year":"2023","unstructured":"Guo, M. et al. Durable and enhanced immunity against SARS-CoV-2 elicited by manganese nanoadjuvant formulated subunit vaccine. Signal Transduct. Target. Ther. 8, 462 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1555_CR29","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","volume":"20","author":"SZ Shalhout","year":"2023","unstructured":"Shalhout, S. Z., Miller, D. M., Emerick, K. S. & Kaufman, H. L. Therapy with oncolytic viruses: progress and challenges. Nat. Rev. Clin. Oncol. 20, 160\u2013177 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1555_CR30","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0022-1759(88)90310-9","volume":"115","author":"T Decker","year":"1988","unstructured":"Decker, T. & Lohmann-Matthes, M. L. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J. Immunol. Methods 115, 61\u201369 (1988).","journal-title":"J. Immunol. Methods"},{"key":"1555_CR31","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1073\/pnas.0915174107","volume":"107","author":"MA Curran","year":"2010","unstructured":"Curran, M. A., Montalvo, W., Yagita, H. & Allison, J. P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl Acad. Sci. USA 107, 4275\u20134280 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1555_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22929-z","volume":"12","author":"DG Roy","year":"2021","unstructured":"Roy, D. G. et al. Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination. Nat. Commun. 12, 2626 (2021).","journal-title":"Nat. Commun."},{"key":"1555_CR33","doi-asserted-by":"publisher","first-page":"4442","DOI":"10.1158\/1078-0432.CCR-20-0305","volume":"26","author":"P Brossart","year":"2020","unstructured":"Brossart, P. The role of antigen spreading in the efficacy of immunotherapies. Clin. Cancer Res. 26, 4442\u20134447 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1555_CR34","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s10120-020-01151-8","volume":"24","author":"K Mimura","year":"2021","unstructured":"Mimura, K. et al. Combined inhibition of PD-1\/PD-L1, Lag-3, and Tim-3 axes augments antitumor immunity in gastric cancer-T cell coculture models. Gastric Cancer 24, 611\u2013623 (2021).","journal-title":"Gastric Cancer"},{"key":"1555_CR35","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1016\/j.cell.2024.04.023","volume":"187","author":"J Zhang","year":"2024","unstructured":"Zhang, J. et al. Osr2 functions as a biomechanical checkpoint to aggravate CD8+ T cell exhaustion in tumor. Cell 187, 3409\u20133426.e24 (2024).","journal-title":"Cell"},{"key":"1555_CR36","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1016\/j.cell.2021.05.038","volume":"184","author":"SX Lu","year":"2021","unstructured":"Lu, S. X. et al. Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. Cell 184, 4032\u20134047 (2021).","journal-title":"Cell"},{"key":"1555_CR37","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1126\/science.abp9563","volume":"380","author":"YE Chen","year":"2023","unstructured":"Chen, Y. E. et al. Engineered skin bacteria induce antitumor T cell responses against melanoma. Science 380, 203\u2013210 (2023).","journal-title":"Science"},{"key":"1555_CR38","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nature14001","volume":"515","author":"M Yadav","year":"2014","unstructured":"Yadav, M. et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515, 572\u2013576 (2014).","journal-title":"Nature"},{"key":"1555_CR39","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1099\/0022-1317-83-8-1953","volume":"83","author":"JA Symons","year":"2002","unstructured":"Symons, J. A., Tscharke, D. C., Price, N. & Smith, G. L. A study of the vaccinia virus interferon-gamma receptor and its contribution to virus virulence. J. Gen. Virol. 83, 1953\u20131964 (2002).","journal-title":"J. Gen. Virol."},{"key":"1555_CR40","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nri3307","volume":"12","author":"SM Kaech","year":"2012","unstructured":"Kaech, S. M. & Cui, W. G. Transcriptional control of effector and memory CD8+ T cell differentiation. Nat. Rev. Immunol. 12, 749\u2013761 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"1555_CR41","first-page":"100771","volume":"18","author":"X Li","year":"2023","unstructured":"Li, X., Sun, X., Wang, B., Li, Y. & Tong, J. Oncolytic virus-based hepatocellular carcinoma treatment: current status, intravenous delivery strategies, and emerging combination therapeutic solutions. Asian J. Pharm. Sci. 18, 100771 (2023).","journal-title":"Asian J. Pharm. Sci."},{"key":"1555_CR42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ccell.2022.10.013","volume":"41","author":"L Lybaert","year":"2023","unstructured":"Lybaert, L. et al. Challenges in neoantigen-directed therapeutics. Cancer Cell 41, 15\u201340 (2023).","journal-title":"Cancer Cell"},{"key":"1555_CR43","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/s41587-023-01796-7","volume":"42","author":"D Ji","year":"2024","unstructured":"Ji, D. et al. An engineered influenza virus to deliver antigens for lung cancer vaccination. Nat. Biotechnol. 42, 518\u2013528 (2024).","journal-title":"Nat. Biotechnol."},{"key":"1555_CR44","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222\u2013226 (2017).","journal-title":"Nature"},{"key":"1555_CR45","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1126\/science.aaf2288","volume":"352","author":"E Stronen","year":"2016","unstructured":"Stronen, E. et al. Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science 352, 1337\u20131341 (2016).","journal-title":"Science"},{"key":"1555_CR46","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s43018-024-00760-x","volume":"5","author":"X Chen","year":"2024","unstructured":"Chen, X. et al. An oncolytic virus delivering tumor-irrelevant bystander T cell epitopes induces anti-tumor immunity and potentiates cancer immunotherapy. Nat. Cancer 5, 1063\u20131081 (2024).","journal-title":"Nat. Cancer"},{"key":"1555_CR47","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41467-019-08534-1","volume":"10","author":"PC Rosato","year":"2019","unstructured":"Rosato, P. C. et al. Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy. Nat. Commun. 10, 567 (2019).","journal-title":"Nat. Commun."},{"key":"1555_CR48","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s43018-022-00335-8","volume":"3","author":"SL Meier","year":"2022","unstructured":"Meier, S. L., Satpathy, A. T. & Wells, D. K. Bystander T cells in cancer immunology and therapy. Nat. Cancer 3, 143\u2013155 (2022).","journal-title":"Nat. Cancer"},{"key":"1555_CR49","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41586-018-0130-2","volume":"557","author":"Y Simoni","year":"2018","unstructured":"Simoni, Y. et al. Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature 557, 575\u2013579 (2018).","journal-title":"Nature"},{"key":"1555_CR50","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s41571-019-0308-z","volume":"17","author":"JD Martin","year":"2020","unstructured":"Martin, J. D., Cabral, H., Stylianopoulos, T. & Jain, R. K. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges. Nat. Rev. Clin. Oncol. 17, 251\u2013266 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1555_CR51","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41571-020-0399-6","volume":"17","author":"C Robert","year":"2020","unstructured":"Robert, C. et al. Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm. Nat. Rev. Clin. Oncol. 17, 707\u2013715 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1555_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00813-3","volume":"9","author":"H Zhao","year":"2024","unstructured":"Zhao, H. et al. A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression. npj Vaccines 9, 22 (2024).","journal-title":"npj Vaccines"},{"key":"1555_CR53","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","volume":"20","author":"AJ Hou","year":"2021","unstructured":"Hou, A. J., Chen, L. C. & Chen, Y. Y. Navigating CAR-T cells through the solid-tumour microenvironment. Nat. Rev. Drug Discov. 20, 531\u2013550 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1555_CR54","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1126\/science.add7034","volume":"382","author":"RL Vincent","year":"2023","unstructured":"Vincent, R. L. et al. Probiotic-guided CAR-T cells for solid tumor targeting. Science 382, 211\u2013218 (2023).","journal-title":"Science"},{"key":"1555_CR55","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/s41551-023-01048-8","volume":"7","author":"AQ Zhang","year":"2023","unstructured":"Zhang, A. Q. et al. Universal redirection of CAR T cells against solid tumours via membrane-inserted ligands for the CAR. Nat. Biomed. Eng. 7, 1113\u20131128 (2023).","journal-title":"Nat. Biomed. Eng."},{"key":"1555_CR56","doi-asserted-by":"publisher","first-page":"eaaz1863","DOI":"10.1126\/scitranslmed.aaz1863","volume":"12","author":"AK Park","year":"2020","unstructured":"Park, A. K. et al. Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors. Sci. Transl. Med. 12, eaaz1863 (2020).","journal-title":"Sci. Transl. Med."},{"key":"1555_CR57","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41586-021-03752-4","volume":"596","author":"JX Caushi","year":"2021","unstructured":"Caushi, J. X. et al. Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature 596, 126\u2013132 (2021).","journal-title":"Nature"},{"key":"1555_CR58","doi-asserted-by":"publisher","first-page":"114238","DOI":"10.1016\/j.addr.2022.114238","volume":"185","author":"W Ngo","year":"2022","unstructured":"Ngo, W. et al. Why nanoparticles prefer liver macrophage cell uptake in vivo. Adv. Drug Deliv. Rev. 185, 114238 (2022).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"1555_CR59","first-page":"1801309","volume":"6","author":"S Suh","year":"2019","unstructured":"Suh, S. et al. Nanoscale bacteria-enabled autonomous drug delivery system (NanoBEADS) enhances intratumoral transport of nanomedicine. Adv. Sci. (Weinh.) 6, 1801309 (2019).","journal-title":"Adv. Sci. (Weinh.)"},{"key":"1555_CR60","first-page":"A575","volume":"10","author":"M G\u00f6genur","year":"2022","unstructured":"G\u00f6genur, M. et al. Intratumoral influenza vaccine in early colorectal cancer. J. Immunother. Cancer 10, A575\u2013A575 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"1555_CR61","doi-asserted-by":"publisher","first-page":"e2204336119","DOI":"10.1073\/pnas.2204336119","volume":"119","author":"JP Townsend","year":"2022","unstructured":"Townsend, J. P., Hassler, H. B., Sah, P., Galvani, A. P. & Dornburg, A. The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2. Proc. Natl Acad. Sci. USA 119, e2204336119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1555_CR62","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1093\/cid\/ciw816","volume":"64","author":"JM Ferdinands","year":"2017","unstructured":"Ferdinands, J. M. et al. Intraseason waning of influenza vaccine protection: evidence from the US Influenza Vaccine Effectiveness Network, 2011-12 through 2014-15. Clin. Infect. Dis. 64, 544\u2013550 (2017).","journal-title":"Clin. Infect. Dis."},{"key":"1555_CR63","doi-asserted-by":"publisher","first-page":"5598","DOI":"10.1016\/j.vaccine.2015.08.082","volume":"33","author":"A Palache","year":"2015","unstructured":"Palache, A., Oriol-Mathieu, V., Fino, M. Xydia-Charmanta, M. & Influenza Vaccine Supply task force (IFPMA IVS). Seasonal influenza vaccine dose distribution in 195 countries (2004\u20132013): little progress in estimated global vaccination coverage. Vaccine 33, 5598\u20135605 (2015).","journal-title":"Vaccine"},{"key":"1555_CR64","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41573-019-0029-0","volume":"18","author":"K Harrington","year":"2019","unstructured":"Harrington, K., Freeman, D. J., Kelly, B., Harper, J. & Soria, J. C. Optimizing oncolytic virotherapy in cancer treatment. Nat. Rev. Drug Discov. 18, 689\u2013706 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1555_CR65","doi-asserted-by":"publisher","first-page":"eabc6659","DOI":"10.1126\/scitranslmed.abc6659","volume":"12","author":"S Atasheva","year":"2020","unstructured":"Atasheva, S. et al. ystemic cancer therapy with engineered adenovirus that evades innate immunity. Sci. Transl. Med. 12, eabc6659 (2020).","journal-title":"Sci. Transl. Med."},{"key":"1555_CR66","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1038\/s41591-022-01937-6","volume":"28","author":"CD Palmer","year":"2022","unstructured":"Palmer, C. D. et al. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nat. Med. 28, 1619\u20131629 (2022).","journal-title":"Nat. Med."},{"key":"1555_CR67","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40425-019-0520-5","volume":"7","author":"A Papachristofilou","year":"2019","unstructured":"Papachristofilou, A. et al. Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. J. Immunother. Cancer 7, 38 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1555_CR68","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","volume":"29","author":"A Mackensen","year":"2023","unstructured":"Mackensen, A. et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat. Med. 29, 2844\u20132853 (2023).","journal-title":"Nat. Med."},{"key":"1555_CR69","doi-asserted-by":"publisher","first-page":"TPS8116","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS8116","volume":"42","author":"JM Lee","year":"2024","unstructured":"Lee, J. M. et al. The phase 3 INTerpath-002 study design: individualized neoantigen therapy (INT) V940 (mRNA-4157) plus pembrolizumab vs placebo plus pembrolizumab for resected early-stage non-small-cell lung cancer (NSCLC). J. Clin. Oncol. 42, TPS8116 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1555_CR70","doi-asserted-by":"crossref","unstructured":"Wang W. et al. HBsAg-tagged tumour vaccine system eliminates solid tumours through virus-specific memory T cells. NCBI https:\/\/www.ncbi.nlm.nih.gov\/bioproject\/PRJNA1300966 (2025).","DOI":"10.1038\/s41551-025-01555-w"}],"container-title":["Nature Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01555-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01555-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01555-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T22:02:06Z","timestamp":1789509726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01555-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":70,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["1555"],"URL":"https:\/\/doi.org\/10.1038\/s41551-025-01555-w","relation":{},"ISSN":["2157-846X"],"issn-type":[{"value":"2157-846X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"6 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}